Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

HitGen works with Scripps and Calibr

by Ann M. Thayer
June 27, 2017 | A version of this story appeared in Volume 95, Issue 18

HitGen, a biotech company based in China with labs in Houston, will work with Scripps Research Institute and its affiliate, the California Institute for Biomedical Research (Calibr). The partners will use HitGen’s DNA-encoded small-molecule libraries to discover and develop oncology, regenerative medicine, and virology drugs. Scripps and Calibr will provide target materials and expertise. The alliance comes just one week after HitGen entered a multiyear drug discovery deal with Pfizer

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.